Previous Close | 1.2100 |
Open | 1.2100 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 65.00 |
Expire Date | 2025-01-17 |
Day's Range | 1.2100 - 1.2100 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
SOMERSET, N.J., May 23, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association’s (EHA) Hybrid Congress.
Discover how Legend Biotech's robust Q1 performance and strategic initiatives are setting the stage for sustained growth.
Q1 2024 Legend Biotech Corp Earnings Call